Kyntra Bio Book Value Per Share Growth & History (KYNB)
Kyntra Bio's book value per share was -$7.42 for fiscal 2025.
View full Kyntra Bio company overviewKyntra Bio annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$7.42 | $48.46 | — |
| 2024 | 2024-12-31 | -$55.88 | -$4.21 | — |
| 2023 | 2023-12-31 | -$51.68 | -$45.98 | — |
| 2022 | 2022-12-31 | -$5.69 | -$61.99 | — |
| 2021 | 2021-12-31 | $56.29 | -$59.13 | −51.23% |
| 2020 | 2020-12-31 | $115.42 | -$31.78 | −21.59% |
| 2019 | 2019-12-31 | $147.20 | -$1.80 | −1.21% |
| 2018 | 2018-12-31 | $149.01 | -$11.14 | −6.96% |
| 2017 | 2017-12-31 | $160.15 | $98.95 | +161.70% |
| 2016 | 2016-12-31 | $61.19 | -$10.42 | −14.55% |
| 2015 | 2015-12-31 | $71.61 | -$22.13 | −23.61% |
| 2014 | 2014-12-31 | $93.74 | $209.08 | — |
| 2013 | 2013-12-31 | -$115.34 | — | — |
Kyntra Bio quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$7.44 | $47.70 | — |
| Q1 2026 | 2026-03-31 | -$10.82 | $42.84 | — |
| Q4 2025 | 2025-12-31 | -$7.42 | $48.46 | — |
| Q3 2025 | 2025-09-30 | -$4.21 | $56.24 | — |
| Q2 2025 | 2025-06-30 | -$55.14 | $2.71 | — |
| Q1 2025 | 2025-03-31 | -$53.66 | $3.67 | — |
| Q4 2024 | 2024-12-31 | -$55.88 | -$4.21 | — |
| Q3 2024 | 2024-09-30 | -$60.45 | -$20.50 | — |
| Q2 2024 | 2024-06-30 | -$57.85 | -$31.82 | — |
| Q1 2024 | 2024-03-31 | -$57.33 | -$44.69 | — |
| Q4 2023 | 2023-12-31 | -$51.68 | -$45.98 | — |
| Q3 2023 | 2023-09-30 | -$39.96 | -$46.96 | — |
| Q2 2023 | 2023-06-30 | -$26.04 | -$53.72 | — |
| Q1 2023 | 2023-03-31 | -$12.64 | -$54.99 | — |
| Q4 2022 | 2022-12-31 | -$5.69 | -$61.99 | — |
| Q3 2022 | 2022-09-30 | $7.00 | -$80.85 | −92.03% |
| Q2 2022 | 2022-06-30 | $27.68 | -$42.66 | −60.65% |
| Q1 2022 | 2022-03-31 | $42.35 | -$58.37 | −57.95% |
| Q4 2021 | 2021-12-31 | $56.29 | -$59.13 | −51.23% |
| Q3 2021 | 2021-09-30 | $87.85 | -$36.39 | −29.29% |
| Q2 2021 | 2021-06-30 | $70.34 | -$39.34 | −35.87% |
| Q1 2021 | 2021-03-31 | $100.73 | -$28.17 | −21.86% |
| Q4 2020 | 2020-12-31 | $115.42 | -$31.78 | −21.59% |
| Q3 2020 | 2020-09-30 | $124.24 | -$46.17 | −27.09% |
| Q2 2020 | 2020-06-30 | $109.69 | -$71.39 | −39.42% |
| Q1 2020 | 2020-03-31 | $128.90 | -$13.10 | −9.22% |
| Q4 2019 | 2019-12-31 | $147.20 | -$1.80 | −1.21% |
| Q3 2019 | 2019-09-30 | $170.40 | $31.53 | +22.71% |
| Q2 2019 | 2019-06-30 | $181.07 | $33.92 | +23.05% |
| Q1 2019 | 2019-03-31 | $142.00 | -$7.70 | −5.14% |
| Q4 2018 | 2018-12-31 | $149.01 | -$11.14 | −6.96% |
| Q3 2018 | 2018-09-30 | $138.87 | -$35.76 | −20.48% |
| Q2 2018 | 2018-06-30 | $147.16 | $66.10 | +81.55% |
| Q1 2018 | 2018-03-31 | $149.70 | $98.59 | +192.90% |
| Q4 2017 | 2017-12-31 | $160.15 | $98.95 | +161.70% |
| Q3 2017 | 2017-09-30 | $174.63 | $103.95 | +147.05% |
| Q2 2017 | 2017-06-30 | $81.06 | $4.11 | +5.34% |
| Q1 2017 | 2017-03-31 | $51.11 | -$11.75 | −18.69% |
| Q4 2016 | 2016-12-31 | $61.19 | -$10.42 | −14.55% |
| Q3 2016 | 2016-09-30 | $70.69 | -$18.01 | −20.31% |
| Q2 2016 | 2016-06-30 | $76.94 | -$28.08 | −26.74% |
| Q1 2016 | 2016-03-31 | $62.86 | -$15.02 | −19.28% |
| Q4 2015 | 2015-12-31 | $71.61 | -$22.13 | −23.61% |
| Q3 2015 | 2015-09-30 | $88.70 | — | — |
| Q2 2015 | 2015-06-30 | $105.03 | — | — |
| Q1 2015 | 2015-03-31 | $77.87 | — | — |
| Q4 2014 | 2014-12-31 | $93.74 | — | — |
Kyntra Bio book value per share trends
Over the last five fiscal years, Kyntra Bio's book value per share decreased from $115.42 to -$7.42, a change of -$122.85. The latest reported quarter, Q2 2026, shows -$7.44.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kyntra Bio source filings ↗